Innovation Pharmaceuticals Inc (IPIX)

[cabel]

I think we are no longer trading days away from the Top Line Data,... but rather trading HOURS away.

My guess less than 15 hours away,... and more like 9 trading hours away from news!

[pix]

It is about time for the OM results.
Tension is building.

[BIzzy]

Its hard for me to imagine that you dont understand what a reasonable inference is...why should I entertain your inferences if they are unsupportable by logic?...why must the Board be the psychiatrist that is forced to listen to your irrational fears?....its bothersome....you can draw any unsupportable and irrational inferences you choose...you just shouldn't expect me to swim in that sea...

[cybermich]

The only reason I am ever compelled to respond (to you know what) is due to the fact we have new shareholders on board.. unfortunately we have this "distraction" STILL.. and it got OLD a long, long time ago...

For any of us who have been here for any length of time.. we know
how ridiculous it is.

Looking forward to Bom results any day/any minute now:)

A true game changer for this company.

Good luck to all REAL IPIX shareholders.

[sox040713]

That’s a great point. I hope everyone realizes that interpreting short volume as actual short sales is incorrect, unless you really believe 50% of Apple’s volume was actual short sales on 12/7.

Let’s compare IPIX’s numbers to Apple’s. Anybody believe these numbers represent shares of Apple actually sold short in the traditional meaning of the the phrase?

[ClayTrader]

* * $IPIX Video Chart 12-07-17 * *

Link to Video - click here to watch the technical chart video

[williamssc]

That's the beauty of being long, low capital gains vs normal income. Can't wait to see that first deal Leo arranges.

[georgejjl]

“With all patients having received treatment, we look forward to wrapping up the Phase 2b Prurisol trial,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “Only a handful of patient follow-up visits remain to be completed. A novel psoriasis drug, particularly one that is oral, safe and effective, would be well-received by clinical practitioners and patients alike, both looking for newer treatment options to help manage this debilitating skin disease.”

http://www.ipharminc.com/press-release/2017/11/30/final-patient-completes-treatment-in-innovation-pharmaceuticals-phase-2b-study-of-oral-prurisol-for-psoriasis

Good luck and GOD bless,

George

[TheDane]

Yes, happy days! I have long $hares so will pay lower taxes on the half I’ll sell when we hit $15.

[williamssc]

At least were no longer talking tax losses.

[TheDane]

Ditto. When I don’t like what’s repeatedly posted I ignore it. These warnings about the Finra data are pointless and just add to the worthless postings.

Like this one of mine!

Go Lagavulin 16!

[Phoenix300]

October 26, 2017
Innovation Pharmaceuticals Aims to Develop First Drug for Approval in Prevention of Oral Mucositis in Head and Neck Cancer Patients as Phase 2 Clinical Trial of Brilacidin Completes
Brilacidin
BEVERLY, Mass., October 26, 2017 (GLOBE NEWSWIRE) – Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the completion of the Phase 2 trial (see link NCT02324335) of Brilacidin-OM for the prevention and treatment of Oral Mucositis (OM) in Head and Neck Cancer (HNC) patients receiving chemoradiation therapy (CRT). The final patient in the Phase 2 randomized, placebo-controlled clinical trial completed their post-therapy follow-up examination this week. The Company has begun the process of closing trial study sites and is now aggregating patient data for top-line analysis, to be reported this quarter.

The primary objectives of the trial are the evaluation of the efficacy of Brilacidin-OM in reducing the incidence of severe OM (WHO Grade ≥3) compared to placebo during seven weeks of study treatment/CRT, and assessment of the safety and tolerability of this novel OM oral rinse therapy. A secondary objective includes evaluating the efficacy of Brilacidin in reducing the duration of severe OM.

The completion of the trial represents an important milestone, positioning the Company to address a significant unmet medical need. There are currently no FDA-approved drugs for preventing OM in patients with Head and Neck Cancer receiving chemoradiation. This painful condition affects upwards of 90 percent of patients in this population as well as a large number of patients receiving CRT for other cancers.

The Company believes that a successful Phase 2 trial would be a major breakthrough. Fast Track designation by the Food and Drug Administration (FDA) for Brilacidin-OM has already been awarded. In addition, the Company plans to apply for FDA Breakthrough Therapy Designation should top-line end of study results reflect similar efficacy (and safety) to that observed at interim, in which patients treated with Brilacidin-OM experienced a markedly reduced rate of severe OM compared to those on placebo.

“By 2030, the global annual incidence of Head and Neck Cancer is expected to exceed 1 million cases,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “It’s a horribly debilitating condition that causes tremendous suffering and leads to corresponding delays in clinical care, adding to costs and complications, for those who experience it. We look forward to compiling and releasing the topline Brilacidin-OM data, toward advancing it into a potential pivotal Phase 3 clinical trial—a final step toward Brilacidin-OM possibly emerging as the world’s first-ever approved preventative treatment for Oral Mucositis in this population.”

[Phoenix300]

November 16, 2017
Innovation Pharmaceuticals Offers Perspectives on Brilacidin as a Potential Preventative Treatment for Oral Mucositis in Head and Neck Cancer Patients
Brilacidin
BEVERLY, Mass., November 16, 2017 (GLOBE NEWSWIRE) – Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide additional perspectives on the planned continued development of Brilacidin-OM for the prevention and treatment of Oral Mucositis (OM) in Head and Neck Cancer (HNC) patients.

As previously announced, the Phase 2 randomized, placebo-controlled clinical trial of Brilacidin-OM (see NCT02324335), enrolling a total of 61 patients, recently was completed, with top-line analysis to be reported shortly.

After unblinding, should final study results compare favorably to those observed at interim, in which patients treated with Brilacidin-OM showed a markedly reduced rate of severe OM (WHO Grade ≥3 ) compared to those on placebo, the Company will initiate an aggressive development plan going forward, including: applying to the Food and Drug Administration (FDA) for Breakthrough Therapy Designation and possibly applying for a similar expedited path in Europe; enhancing oral rinse administration with patient-friendly formulation and packaging; and, dedicating internal resources to Phase 3 trial design planning and execution.

Formal collaboration with pharmaceutical companies that have expressed an interest in partnering Brilacidin-OM may well assist further with expediting the drug candidate’s development timetable. Some of these partnering conversations have matured to the point of potentially structuring mutually beneficial licensing agreements, pending the final Phase 2 study results.

“We very much look forward to taking what could be the final step in Brilacidin’s development for the prevention of OM—top-line results reporting followed by possible advancement into a pivotal Phase 3 trial,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “The OM market comprises a huge unmet medical need. To think we might one day help end the pain of so many patients suffering from OM, better enabling them to get the critical cancer care they need, would be an incredible accomplishment for Innovation Pharmaceuticals’ staff and a proud moment for our shareholders. Furthermore, securing partnerships with Pharma would represent a significant milestone for the Company, further anchoring the rapidly expanding Brilacidin Franchise.”

“What’s important to understand about Brilacidin-OM, at this stage of its development, is that it truly represents a potential breakthrough treatment in OM,” commented Arthur P. Bertolino, MD PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “A majority of OM treatments currently being evaluated in clinical trials still target reduction in duration of OM symptoms, rather than going after OM prevention—what we’ve established as our primary efficacy outcome in the completed Phase 2 trial. We’ve set for ourselves a high bar, to be sure, but feel confident that if we deliver strong top-line results, Brilacidin-OM will stand apart from any future competition—a potential first-to-market and best-in-class OM treatment.”

About Oral Mucositis

Oral Mucositis (OM) is a frequent, painful and debilitating complication of chemoradiation. Head and Neck Cancer (HNC) patients—comprising an estimated 65,000 newly diagnosed cases in the U.S. alone in 2017, and an estimated 700,000 worldwide (source: GLOBOCAN)—are at the greatest risk of developing OM (a 90 to 100 percent rate of occurrence). By 2030, the global incidence of HNC cases is expected to exceed 1 million per year. Moreover, between 25 and 60 percent of cancer patients, regardless of cancer type, also will experience OM. Characterized by inflammation and ulceration, patients suffering from OM are often unable to speak and eat (requiring the insertion of a feeding tube) and are more susceptible to infections, with severe cases leading to hospitalization at increased treatment costs of up to $25,000. There currently are no approved medications for the prevention of OM in the HNC population, with only limited palliative care options available. Worldwide, the potential market for OM is expected to exceed $1 billion in the next few years

[Blue Fin]

If true we now have 40 million shares shorted according to Allen C.

[F1ash]

Let’s compare IPIX’s numbers to Apple’s. Anybody believe these numbers represent shares of Apple actually sold short in the traditional meaning of the the phrase?


Volum Short Volume % of Vol Shorted
Dec 07 6,556,715 3,299,550 50.32%
Dec 06 7,371,192 3,334,647 45.24%
Dec 05 8,043,649 4,003,499 49.77%
Dec 04 8,518,971 4,347,358 51.03%
Dec 01 10,462,61 4,786,297 45.75%
Nov 30 9,066,499 2,624,634 28.95%

http://nakedshortreport.com/company/AAPL

[keltoi]

Yada yada yada.Finra's statements are obtuse at best and the constant dribble on this ongoing argument about shorts and naked shorts is dead in the water.Let the F#(+ing thing die a natural death.

Kelt

[sox040713]

New investors, the statement "42% of today's volume was short sales" wasn’t in the source file. The most recent short interest is < 1% of the OS and the most recent failure-to-deliver (naked short) # is a measly 25,662 shares. IMHO interpreting short volume as actual short sales is incorrect. This is what FINRA, the exact same source which you used to post the #, said.

"Thank you for contacting FINRA’s Office of the Ombudsman. Regarding your question, it would be incorrect to assume that short sales comprise 32% of the total volume on that trading day for IPIX. FINRA publishes the daily short sale volume pursuant to an SEC mandate; however, there are various trading anomalies that result in the reported short sale volume often being exaggerated. Thus, the true total short sales volume may be significantly lower than the volume that is reported. Third parties sometimes ignore this and try to claim the ratio is valid to further their own objectives."

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135537542

You can also check out these two posts for some detailed explanations.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133263103

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132584168

Here are the official short interest and failure-to-deliver data.

Settlement Date: 10/31/2017
Current Short: 1,274,605
Previous Short: 1,227,218
Change: 47,386 (3.86%)
Average Daily Volume: 361,557
Days to Cover: 3.53

0.91% of the outstanding shares were short.

http://otce.finra.org/ESI

“In a “naked” short sale, the seller does not borrow or arrange to borrow the securities in time to make delivery to the buyer within the standard three-day settlement period.[3] As a result, the seller fails to deliver securities to the buyer when delivery is due (known as a ”failure to deliver” or “fail”).”

https://www.sec.gov/investor/pubs/regsho.htm

According to the SEC, only 25,662 shares (0.018% of the OS) were failure-to-deliver as of October 31.

20171031|45782D100|IPIX|25662|INNOVATION PHARMACEU|0.79

https://www.sec.gov/data/foiadocsfailsdatahtm

[To infinity and beyond!]

perhaps you would like to make an inference anyway, which is all that I am considering

why does that bother you so much? if someone has any shadow of doubt about any IP product-

why is that so hard for you ?

[williamssc]

Sad how some will come on and blatantly use scare tactics hoping to effect stock price. Over the years many just like that have come and gone.

[BooDog]

Not that $IPIX has some ground breaking potentially life saving data on the way but it seems that some keep running in circles.

So, putting it as simple as I can, people die from not being able to get the nutrition they need to survive from head and neck cancer treatment / therapy. This stuff eats you up. A patient that has an excellent chance of 100% recovery through surgery and then has to deal with mucositis can not only be debilitating, it can be deadly. And watching a loved one go through this is just as terrible. Seeing is believing. Let's hope brilacidin is as good as we hope it is.

$IPIX

[DaysOnTheBeach]

More Nonsense!!!!! Have you ever heard of SEC Form 4 filings? Those are the public notifications that must be released within a few days of officers of a company buying or selling shares.

So... daily you accuse IPIX management of selling shares, your implication being that they're bailing out, and I guess "sticking it" to shareholders. So... where are the Form 4 documents? Where? There aren't any, that's where. They're your fantasy. Your accusations are absolutely false.

DOTB

[DaysOnTheBeach]

Nonsense!!! It's Aspire that's made shareholder wealth possible!!!

All pre-revenue biotech companies have to get funding from somewhere, and IPIX's deal with Aspire has been an excellent choice. Without funding IPIX would not have been able to afford the platform development and clinical trials that make it the company on the threshold of greatness that it is today.

[AlanC]

FINRA short sales of IPIX
20171207|IPIX|225949|0|541836|O
42% of today's volume was short sales!
Go IPIX!!!
http://regsho.finra.org/FORFshvol20171207.txt

[williamssc]

One of many, but what I look at is the scope of the asset. OM preventative equates industry standard.

[untohim]

this is just 1 application

[williamssc]

I agree. B for OM is an industry game changer.

[untohim]

OH! it will be inconsequential alright!

No inconsequential day of the week

as always, aimho :)

[scottsmith]

Wait and see. Great OM results will stand on their own and reverberate throughout the ages. No inconsequential day of the week will hold back a preventative for OM.

[BIzzy]

idiotic supposition drawn from thin air to fit a preconceived position....there are not enough facts available on the interim release issue to make a reasonable inference....

[untohim]

You sure about that smith? :)

Leo will not sit on results.

[scottsmith]

Today was Day 8 since the Cox Report. On November 30, Cox wrote that Leo had told the author OM results would be released in about a week. I think it reasonable to assume that Cox spoke with our Uncle Leo before the 30th. That would put us at at out least Day 9.

OM results could be made public as soon as tomorrow morning. Leo will not sit on results.

[sixmilliondollarbios]

Data expected Monday. Tomorrow will be up.

[TheDane]

Good idea. I haven’t seen that done since the early days of the Internet. Maybe some companies still do it. I think that Alzheimer’s company did it effectively when it was running crazy a couple years ago but hats he only one I recall recently.

Go LEO! .

[TheDane]

Swell. Right on cue. Hopefully you’ll be on the side of The Force and not the Dark side.

[untohim]

ichimoku chart very telling...look for a strong push to drop the stock 2 pennies tomorrow...then a very short trading range....until we see bom results .....P results....bup results....meanwhile that .92 - 1.17 spread gets pounded even further to flat line...all imho

[Bruinfan4ever]

Yep, but the big difference than before is that there has been a lot more volume than before and the stock traded many shares over the 200 MDA.

Yep so it could drop but you clearly can't call them similar cases from the last two times. This run is clearly different.

[sox040713]

Agreed that the $150M MC (~$1.07 SP) is a good consolidation point. I see IPIX to have at least a $200M MC (~$1.43 SP) if B-OM is successful. Will Leo give us a really happy Friday tomorrow?

.60's/.70's to over the $ in just a matter of days earns some decent consolidation.

[Bruinfan4ever]

Dud thinks everybody is selling shares. Including him.

[top123]

Pete - Like that theory !!!

[sox040713]

More BS. Management has to file Form 4 if they sold today.

[123tom]

yes,that's correct..

it would 'amount to buying back some shares I sold the other day'

it was for me, good money management,playing the odds, etc.
93 cents now, is not the same "93" as it was a week ago. It was a resistance target last week and its a support target now.

I also hope nobody makes decisions based on just my TA, or anyone else's.

If there might be a little dip to start tomorrow, could become the last dip to buy here before news comes.

just for giggles, I'll bet we get a little plunge at the open. maybe hits 95.

[petemantx]

I would love to see an after hours announcement so that a major buildup could come about. Why not do it tomorrow at close so that the entire weekend could be a pressure cooker for those wanting to get in?

Sure would make Monday an exciting day! Take the traders by surprise and the shorters as well. Reward those who have already placed their bets on the company.

[noretreat]

I'm in for more tomorrow/Monday on any pullback.

[Cherry_11]

A stink bid for what, to buy back the 1000 shares that you sold other day?!? Ha. Come on, your technical analysis commentary is getting redundant. Sure, it could go down tomorrow anyone can guess that. But chances are that hesitant investors and people reading this board are gonna miss the boat when they wake up to a press release that causes a 50-100% pop when the market opens.

And you’re excited about saving $80-$100 bucks on your next share purchase! Funny stuff Tommy??.

Anyways, I just hope people aren’t waiting to get in at lower prices with your TA. Because they are going to be kicking themselves for not grabbing the bull by the horns...

Go IPIX

GO LEO! Release the Kraken!

PS. I just convinced myself to add tomorrow! Treasure chest of IPIX shares is getting pretty damn heavy!

[scottsmith]

Watch Clay Traders video. He is very bullish and stated today’s action was better than another move up.

[williamssc]

Yes. Great point.

[MinnieM]

Aspire made it possible for the company to purchase the Brilacidin platform in addition to running clinical trials. That purchase was brilliant.

Also, management isn't selling, unless they have a deal with a bp we aren't aware of yet.

[williamssc]

What a crock. Management is not selling unless
we have Possible deal very soon.

[williamssc]

Wrong dud. Aspire only funds this company and has funded this company through several positive trials. Aspire made it possible for IPIX to succeed in spite of the plethora of negative attacks.

[Bruinfan4ever]

Spot on with what?

"That it won't happen at all?" good choice.